Global 
Sverige 
USA Stille AB: Interim Report Q2 2023
Stille AB (publ) publishes the report for the second quarter and first half of the business year 2023. ”Strong sales growth, profitability and cashflow in the second quarter”, summarizes President and CEO Torbjörn Sköld.
Revenue increased in the second quarter by 18.6 percent to 75.1 MSEK (63.3) after strong growth from both business units.
“I am pleased to see the continued strong growth compared to previous year given that the first half year last year was a record period”, comments Torbjörn Sköld.
The gross profit amounted to 44.6 percent (45.4). Business unit Surgical Tables was affected by an unfavorable product and market mix, while Surgical Instruments was positively affected by the same factors. Operating profit amounted to 11.9 MSEK (8.9).
”Stille’s strategic and financial goals remain. With our high-quality products within surgical instruments and radiolucent surgical tables, we will operate in niche premium segments. The first half of 2023 was strong for Stille. We continue to deliver value to our customers, which creates good demand, strong growth and good cashflow”, concludes Stille’s CEO.
| MSEK | APR-JUN 2023 |
APR-JUN 2022 |
JAN-JUN 2023 |
JAN-JUN 2022 |
JUL-JUN 2022/23 |
JAN-DEC 2022 |
| Revenue | 75.1 | 63.3 | 147.5 | 124.9 | 268.9 | 246.3 |
| Gross Profit Margin, % | 44.6 | 45.4 | 43.5 | 45.1 | 43.7 | 45.3 |
| EBITDA, before one-time costs | 15.7 | 11.2 | 29.4 | 21.0 | 50.5 | 42.1 |
| EBITDA | 15.7 | 11.2 | 26.1 | 21.0 | 47.2 | 42.1 |
| Operating Profit, before one-time costs |
11.9 | 8.9 | 22.4 | 16.4 | 38.5 | 32.5 |
| Operating Profit | 11.9 | 8.9 | 19.1 | 16.4 | 35.1 | 32.4 |
| Operating Profit, % | 15.9 | 14.0 | 12.9 | 13.2 | 12.9 | 13.2 |
Torshälla, July 14th, 2023.
This information is such information that Stille AB is obliged to disclose according to the EU’s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on July 14th, 2023, kl. 08.00 (CEST).
Attachments
Interim Report Q2 2023 (Only in Swedish)
Press Release - Interim Report Q2 2023
For more information, please contact:
Torbjörn Sköld
CEO and President
+46 (0)70 316 63 91 | torbjorn.skold@stille.se
Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s main business areas are surgical instruments and c-arm tables. Stille’s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym “STIL” with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se.
